A standard evolvability score for every tumour
Some tumours change fast and escape drugs quickly; others are stable. A single validated score for how evolvable a tumour is would tell doctors how aggressively to combine treatments.
Copy-number heterogeneity, whole-genome doubling, chromosomal instability signatures, APOBEC activity and ctDNA turnover each predict evolution and relapse in separate studies. The proposal is to define, freeze and prospectively validate one composite evolvability index computed from routine sequencing, analogous to how tumour mutational burden was standardised.
- Tumour heterogeneity and clonal evolution · A tumour is many tumours. Treatments that kill most cells leave the rest to grow back, changed.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Pages like this
not linked directly; found by shared links- Key paperTCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features
Shares Mutational signature, Tumour mutational burden (TMB), Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
- InstitutionOntario Institute for Cancer Research
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- PersonGad Getz
Shares Mutational signature, Whole-exome & whole-genome sequencing.
- Key paperCancer genome landscapes: about 140 driver genes, and each tumour needs only a handful
Shares Mutational signature, Tumour mutational burden (TMB), Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
- IdeaA single calibrated tumour mutational burden across all sequencing panels
Shares Tumour mutational burden (TMB), Whole-exome & whole-genome sequencing, Biomarkers are not validated or standardised.
- IdeaBank three spatially separate tumour blocks from every resection
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing, Comprehensive genomic profiling.
- IdeaSlow the tumour's mutation engine with APOBEC inhibitors during targeted therapy
Shares Mutational signature, Tumour heterogeneity and clonal evolution.
- IdeaLabel every targetable mutation as truncal or branch on the report
Shares Tumour heterogeneity and clonal evolution, Biomarkers are not validated or standardised, Comprehensive genomic profiling.